Inks ES - Search Results

1

Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.

Li X, Inks ES, Li X, Hou J, Chou CJ, Zhang J, Jiang Y, Zhang Y, Xu W. Li X, et al. Among authors: inks es. J Med Chem. 2014 Apr 24;57(8):3324-41. doi: 10.1021/jm401877m. Epub 2014 Apr 15. J Med Chem. 2014. PMID: 24694055 Free PMC article.

2

Histone deacetylase inhibitors with enhanced enzymatic inhibition effects and potent in vitro and in vivo antitumor activities.

Zhang L, Zhang Y, Chou CJ, Inks ES, Wang X, Li X, Hou J, Xu W. Zhang L, et al. Among authors: inks es. ChemMedChem. 2014 Mar;9(3):638-48. doi: 10.1002/cmdc.201300297. Epub 2013 Nov 12. ChemMedChem. 2014. PMID: 24227760 Free PMC article.

3

Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor.

Duan W, Li J, Inks ES, Chou CJ, Jia Y, Chu X, Li X, Xu W, Zhang Y. Duan W, et al. Among authors: inks es. J Med Chem. 2015 May 28;58(10):4325-38. doi: 10.1021/acs.jmedchem.5b00317. Epub 2015 May 7. J Med Chem. 2015. PMID: 25906087 Free PMC article.

4

Development of Allosteric Hydrazide-Containing Class I Histone Deacetylase Inhibitors for Use in Acute Myeloid Leukemia.

McClure JJ, Zhang C, Inks ES, Peterson YK, Li J, Chou CJ. McClure JJ, et al. Among authors: inks es. J Med Chem. 2016 Nov 10;59(21):9942-9959. doi: 10.1021/acs.jmedchem.6b01385. Epub 2016 Oct 26. J Med Chem. 2016. PMID: 27754681 Free PMC article.

5

Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study.

Li X, Zhang Y, Jiang Y, Wu J, Inks ES, Chou CJ, Gao S, Hou J, Ding Q, Li J, Wang X, Huang Y, Xu W. Li X, et al. Among authors: inks es. Eur J Med Chem. 2017 Jul 7;134:185-206. doi: 10.1016/j.ejmech.2017.03.069. Epub 2017 Mar 30. Eur J Med Chem. 2017. PMID: 28415009 Free PMC article.

6

Class I HDAC Inhibitors Display Different Antitumor Mechanism in Leukemia and Prostatic Cancer Cells Depending on Their p53 Status.

Li X, Peterson YK, Inks ES, Himes RA, Li J, Zhang Y, Kong X, Chou CJ. Li X, et al. Among authors: inks es. J Med Chem. 2018 Mar 22;61(6):2589-2603. doi: 10.1021/acs.jmedchem.8b00136. Epub 2018 Mar 9. J Med Chem. 2018. PMID: 29499113 Free PMC article.

7

Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors.

Zhao C, Zang J, Ding Q, Inks ES, Xu W, Chou CJ, Zhang Y. Zhao C, et al. Among authors: inks es. Eur J Med Chem. 2018 Apr 25;150:282-291. doi: 10.1016/j.ejmech.2018.03.002. Epub 2018 Mar 6. Eur J Med Chem. 2018. PMID: 29533873

8

Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity.

Li X, Jiang Y, Peterson YK, Xu T, Himes RA, Luo X, Yin G, Inks ES, Dolloff N, Halene S, Chan SSL, Chou CJ. Li X, et al. Among authors: inks es. J Med Chem. 2020 May 28;63(10):5501-5525. doi: 10.1021/acs.jmedchem.0c00442. Epub 2020 May 6. J Med Chem. 2020. PMID: 32321249 Free PMC article.

9

A novel class of small molecule inhibitors of HDAC6.

Inks ES, Josey BJ, Jesinkey SR, Chou CJ. Inks ES, et al. ACS Chem Biol. 2012 Feb 17;7(2):331-9. doi: 10.1021/cb200134p. Epub 2011 Nov 11. ACS Chem Biol. 2012. PMID: 22047054 Free PMC article.

10

Structure-activity relationship study of vitamin k derivatives yields highly potent neuroprotective agents.

Josey BJ, Inks ES, Wen X, Chou CJ. Josey BJ, et al. Among authors: inks es. J Med Chem. 2013 Feb 14;56(3):1007-22. doi: 10.1021/jm301485d. Epub 2013 Jan 30. J Med Chem. 2013. PMID: 23327468 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

16 results

Search Page

Filters